Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
45.12
USD
|
-8.35%
|
|
+19.08%
|
+12.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
131.3
|
153.7
|
32.72
|
16.16
|
1,228
|
1,508
|
-
|
-
|
Enterprise Value (EV)
1 |
131.3
|
153.7
|
32.72
|
16.16
|
1,058
|
1,369
|
1,408
|
1,508
|
P/E ratio
|
-3.27
x
|
-4.95
x
|
-1.05
x
|
-0.69
x
|
-17.1
x
|
-28.9
x
|
-59.9
x
|
43.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
33.5
x
|
9.97
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
31.3
x
|
9.97
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-42.4
x
|
-28.3
x
|
-982
x
|
22.4
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-2.36%
|
-3.53%
|
-0.1%
|
4.47%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,977
|
5,308
|
5,320
|
8,159
|
30,499
|
33,411
|
-
|
-
|
Reference price
2 |
44.10
|
28.95
|
6.150
|
1.980
|
40.25
|
45.12
|
45.12
|
45.12
|
Announcement Date
|
3/4/20
|
3/3/21
|
3/31/22
|
3/21/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
44.94
|
151.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-23.49
|
-36.29
|
-31.53
|
-24.4
|
-41.38
|
-58.07
|
-30.84
|
59.59
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-68.62%
|
39.4%
|
Earnings before Tax (EBT)
1 |
-30.77
|
-24.64
|
-30.91
|
-24.07
|
-38.99
|
-57.77
|
-30.81
|
59.61
|
Net income
1 |
-30.77
|
-24.64
|
-30.91
|
-24.07
|
-38.99
|
-57.77
|
-30.81
|
38.87
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-68.55%
|
25.7%
|
EPS
2 |
-13.50
|
-5.850
|
-5.850
|
-2.870
|
-2.360
|
-1.563
|
-0.7533
|
1.034
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-24.94
|
-48.3
|
-1.433
|
67.37
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3.19%
|
44.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
173.3%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/3/21
|
3/31/22
|
3/21/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.286
|
-3.001
|
-5.773
|
-6.779
|
-6.235
|
-5.61
|
-8.469
|
-8.623
|
-10.38
|
-13.91
|
-13.06
|
-13.64
|
-14.51
|
-17.19
|
-13.83
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.14
|
-2.828
|
-5.724
|
-6.725
|
-6.132
|
-5.486
|
-8.356
|
-8.475
|
-10.86
|
-11.3
|
-12.99
|
-13.58
|
-14.42
|
-17.1
|
-13.83
|
Net income
1 |
-8.14
|
-2.828
|
-5.724
|
-6.725
|
-6.132
|
-5.486
|
-8.356
|
-8.475
|
-10.86
|
-11.3
|
-12.99
|
-13.58
|
-14.42
|
-17.1
|
-13.83
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.500
|
-0.6000
|
-1.050
|
-0.9000
|
-0.7600
|
-0.5800
|
-0.8800
|
-0.8100
|
-0.9500
|
-0.3300
|
-0.3683
|
-0.3750
|
-0.3867
|
-0.4400
|
-0.3900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/31/22
|
5/10/22
|
8/10/22
|
11/9/22
|
3/21/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
170
|
139
|
99.6
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-24.9
|
-48.3
|
-1.43
|
67.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
-
|
-
|
-
|
-
|
1
|
1
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
2.23%
|
-
|
Announcement Date
|
3/4/20
|
3/3/21
|
3/31/22
|
3/21/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
45.12
USD Average target price
65.17
USD Spread / Average Target +44.43% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.10% | 1.51B | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|